Physician profile
Nathan Jacobson
NPI 1396742581
$8,599.07
in general payments reported to CMS, 2019-2025
24 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 84% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $880 · 2020: $497 · 2021: $873 · 2022: $1,755 · 2023: $1,371 · 2024: $1,543 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,577 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,577.03 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $2,159.03 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $1,306.05 | 2021-2025 | |
| Insmed, INC. | $1,242.39 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $831.83 | 2019-2023 | Symtuza |
| Gilead Sciences, INC. | $666.49 | 2019-2025 | Biktarvy, Veklury |
| Merck Sharp & Dohme LLC | $604.86 | 2019-2025 | Zerbaxa, Pifeltro, Dificid |
| Allergan, INC. | $349.64 | 2019-2020 | |
| Astellas Pharma US INC | $319.33 | 2019-2023 | Cresemba |
| Paratek Pharmaceuticals, INC. | $236.12 | 2019-2025 | Nuzyra |
| Cumberland Pharmaceuticals, INC. | $143.26 | 2019-2024 | Vibativ |
| Janssen Products, LP | $139.97 | 2021-2022 | |
| Melinta Therapeutics, LLC | $125.87 | 2020-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Shionogi INC | $115.13 | 2022-2023 | Fetroja |
| Aimmune Therapeutics, INC. | $97.77 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $50.52 | 2022-2025 | Rebyota |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $38.61 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $31.08 | 2019-2021 | |
| Invivyd INC | $28.48 | 2025 | Pemgarda |
| Theratechnologies INC. | $27.65 | 2023 | Trogarzo, Egrifta |
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2022 | |
| Octapharma USA, INC. | $17.21 | 2019 | |
| Pfizer INC. | $16.99 | 2025 | |
| Nabriva Therapeutics, Plc | $14.81 | 2021 | |
| La Jolla Pharmaceutical Company | $13.99 | 2025 | Zevtera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.